$NORD

Nordicus Partners Corp

Nordicus Partners is a U.S. publicly listed biotechnology company that acquires and develops drugs from early-stage life sciences companies in the Nordic region. It focuses on therapeutics for diseases with unmet medical needs, with a scientific focus on inflammation and immune modulation. Its portfolio includes Orocidin, which develops QR-01 for periodontitis; Bio-Convert, which develops QR-02 for oral leukoplakia; and NoviThera, which develops QR-04, a monoclonal antibody treatment for psoriasis. Nordicus scouts companies, offers selected businesses an accelerator program with capital, resources and advice, and typically seeks to acquire them after milestones are met. It aims to develop portfolio drugs through Phase I, then may pursue a sale or merger, further development, a pharmaceutical partnership or a standalone IPO. Nordicus is headquartered in Beverly Hills, California.

No enriched coverage for $NORD in the last 7 days.

No SEC Form 4 filings for $NORD in the last 30 days.

See all $NORD insider activity →

Nordicus Partners Raises $1 Million Through Four Convertible Notes

Nordicus Partners raised $1 million by issuing four $300,000 convertible notes to investors, each with 5% interest and maturing in 2027. Investors received commitment shares, with conversion allowed after 2027 or in default, at 90% of the 10-day average price. The company agreed to register conversion shares for resale, according to an SEC filing.

NORD sentiment & insider activity

Recent NORD coverage spans corporate actions and insider activity.

What's driving NORD

AlphAI scores every news story that mentions NORD with an AI model for sentiment and relevance, and aggregates insider trades from Nordicus Partners Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $NORD

Score

Nordicus Partners Raises $1 Million Through Four Convertible Notes

Nordicus Partners raised $1 million by issuing four $300,000 convertible notes to investors, each with 5% interest and maturing in 2027. Investors received commitment shares, with conversion allowed after 2027 or in default, at 90% of the 10-day average price. The company agreed to register conversion shares for resale, according to an SEC filing.

$NORDLowOffering· $1M · closed

Nordicus Partners Corp (NORD): Entry into a Material Definitive Agreement

Nordicus Partners Corp (NORD) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On November 5, 2026, Nordicus Partners Corporation (“we” or the “Company”) issued to Keystone Capital Partners LLC (“Keystone”), Seven Knots, LLC, 5T Capital Partners, LP and Creo Investments LLC (collectively, the “ Investors

$NORDLowOffering· $80K · closed

Nordicus Partners Corp (NORD): Unregistered Sales of Equity Securities

Nordicus Partners Corp (NORD) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02. Unregistered Sales of Equity Securities. In July and October 2026, we received subscription commitments from two private investors for a total of 40,000 restricted shares of our common stock, par value $0.001 per share. The price per share was $2.00. The proceeds to us

$NORDLowDebt financing· $147K

Nordicus Partners Corp (NORD): Entry into a Material Definitive Agreement

Nordicus Partners Corp (NORD) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 15, 2026, Nordicus Partners Corporation (“we” or the “Company”) issued to ABCHill Holding ApS (the “Lender”) a Promissory Note (the “Note”) in the principal amount of $147,000. The Note is payable on demand and bear

$NORDLowDebt financing· $75K

Nordicus Partners Corp (NORD): Entry into a Material Definitive Agreement

Nordicus Partners Corp (NORD) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 8, 2026, Nordicus Partners Corporation (“we” or the “Company”) issued to AC Nordic ApS (the “Lender”) a Promissory Note (the “Note”) in the principal amount of $75,000. The Note is payable on demand and bears intere

Related tickers